BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | May 21, 2019
Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
BioCentury | Feb 22, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
BioCentury | Feb 20, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
BioCentury | Oct 11, 2017
Preclinical News

Team identifies HIF2A as liver disease target

A paper published in Nature Medicine by researchers at the National Cancer Institute and colleagues identified intestinal endothelial PAS domain protein 1 ( HIF2A ; HIF-2alpha ; EPAS1) as a promising target to treat hepatic steatosis....
BioCentury | Sep 5, 2016
Company News

Cerulean cancer news

Cerulean will reduce headcount by 21 (48%) to 23 after lead candidate CRLX101 missed the primary endpoint in a Phase II trial to treat metastatic renal cell carcinoma (RCC) in combination with Avastin bevacizumab. CRLX101...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: HIF1A antisense RNA 2 (HIF1A-AS2)

...and mouse studies suggest inhibiting HIF1A-AS2 could help treat glioblastoma multiforme (GBM). In GBM patients, HIF1A-AS2...
...than in adjacent normal brain tissue. In a mouse model of GBM, tumor-targeted shRNA against HIF1A-AS2...
...Next steps could include identifying and testing HIF1A-AS2 inhibitors in animal models of GBM. TARGET/MARKER/PATHWAY: HIF1A antisense RNA 2 (HIF1A-AS2)...
BioCentury | Oct 1, 2015
Product R&D

Escaping the liver

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to its technology...
BioCentury | Jul 13, 2015
Company News

NantWorks, Sorrento deal

Sorrento and NantWorks formed a JV to develop small molecules to treat cancer. The companies will jointly provide $100 million; NantWorks will own 60% of the JV, and Sorrento will own the remainder. The JV...
BioCentury | Jul 10, 2015
Company News

Sorrento, NantBioScience form oncology JV

Sorrento Therapeutics Inc. (NASDAQ:SRNE) and the NantBioScience Inc. subsidiary of NantWorks LLC (Los Angeles, Calif.) formed a joint venture to develop small molecules to treat cancer. The companies will jointly supply $100 million; NantBioScience will...
Items per page:
1 - 10 of 14